Furthermore, more than half of the patients who reverted from MO achieved a ≥ 50% reduction in the monthly average number of headache days of at least moderate severity after treatment with fremanezumab quarterly (66/111 [59.5%]) or monthly (67/120 [55.8%]); of those treated with placebo, 27.6% (24/87) achieved a ≥ 50% reduction (Fig. 4b). Among patients who continued to experience MO, the proportion of patients with a ≥ 50% reduction in the monthly average number of headache days of at least moderate severity was 4.4% (4/90) with fremanezumab quarterly, 14.1% (11/78) with fremanezumab monthly, and 2.0% (2/101) with placebo (Fig. 4b).